Access the full text.
Sign up today, get DeepDyve free for 14 days.
Z. Motovska, P. Widimsky, R. Petr, D. Bílková, I. Marinov, S. Simek, P. Kala (2010)
Optimal pretreatment timing for high load dosing (600 mg) of clopidogrel before planned percutaneous coronary intervention for maximal antiplatelet effectiveness.International journal of cardiology, 144 2
D. Cutlip, S. Windecker, R. Mehran, A. Boam, D. Cohen, G. Es, P. Steg, M. Morel, L. Mauri, P. Vranckx, E. Mcfadden, A. Lansky, M. Hamon, M. Krucoff, P. Serruys (2007)
Clinical End Points in Coronary Stent Trials: A Case for Standardized DefinitionsCirculation, 115
(2009)
Clopidogrel responsiveness and TRAP‐6 induced aggregometry: A study in patients on chronic anti‐platelet treatment
S. Jolly, J. Pogue, K. Haladyn, R. Peters, K. Fox, Á. Avezum, B. Gersh, H. Rupprecht, S. Yusuf, S. Mehta (2008)
Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study.European heart journal, 30 8
G. Stone, B. Witzenbichler, G. Guagliumi, J. Peruga, B. Brodie, Dariusz Dudek, Ran Kornowski, Franz Hartmann, B. Gersh, S. Pocock, G. Dangas, S. Wong, Ajay Kirtane, H. Parise, R. Mehran (2008)
Bivalirudin during primary PCI in acute myocardial infarction.The New England journal of medicine, 358 21
I. Mrdovic, L. Savic, J. Perunicić, M. Ašanin, R. Lasica, J. Marinković, Z. Vasiljevic, M. Ostojić (2009)
Development and validation of a risk scoring model to predict net adverse cardiovascular outcomes after primary percutaneous coronary intervention in patients pretreated with 600 mg clopidogrel: rationale and design of the RISK-PCI study.Journal of interventional cardiology, 22 4
I. Mrdovic, L. Savic, G. Krljanac, M. Ašanin, J. Perunicić, R. Lasica, J. Marinković, N. Kocev, Z. Vasiljevic, M. Ostojić (2013)
Predicting 30-day major adverse cardiovascular events after primary percutaneous coronary intervention. The RISK-PCI score.International journal of cardiology, 162 3
Deepak Bhatt, J. Scheiman, N. Abraham, E. Antman, Francis Chan, C. Furberg, David Johnson, K. Mahaffey, E. Quigley, R. Harrington, E. Bates, C. Bridges, M. Eisenberg, V. Ferrari, M. Hlatky, S. Kaul, J. Lindner, D. Moliterno, D. Mukherjee, R. Schofield, R. Rosenson, J. Stein, H. Weitz, D. Wesley (2008)
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.Journal of the American College of Cardiology, 52 18
W. Ahmad (2009)
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes.
W. Wijns, Chairperson, Belgium, P. Kolh, N. Danchin, France, Carlo Di, Mario, K. Huber, S. James, Juhani Sweden, Jose Knuuti, Lopez-Sendon, J. Spain, France Marco, L. Menicanti, Italy, M. Ostojić, Massimo Serbia, Charles Piepoli, Pirlet, Jose Belgium, Pomar, Nicolaus Spain, Reifart, Flavio Germany, Martin Ribichini, Paul Schalij, Sergeant, Patrick Belgium, S. Serruys, Silber, M. Germany, Sousa Uva, Humberto Sanmartin
Guidelines on Myocardial Revascularization the Task Force on Myocardial Revascularization of the European Society of Cardiology (esc) and the European Association for Cardio-thoracic Surgery (eacts) Developed with the Special Contribution of the European Association for Percutaneous Cardiovascular I
A. Bellemain‐Appaix, D. Brieger, F. Beygui, J. Silvain, A. Pena, G. Cayla, O. Barthelemy, J. Collet, G. Montalescot (2010)
New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis.Journal of the American College of Cardiology, 56 19
T. Cuisset, C. Frère, J. Quilici, F. Barbou, P. Morange, T. Hovasse, J. Bonnet, M. Alessi (2006)
High post‐treatment platelet reactivity identified low‐responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndromeJournal of Thrombosis and Haemostasis, 4
I. Mrdovic, L. Savic, G. Krljanac, M. Ašanin, J. Perunicić, N. Antonijević, R. Lasica, J. Marinković, N. Kocev, Z. Vasiljevic (2013)
Impact of high post-loading platelet aggregation on 30-day clinical outcomes after primary percutaneous coronary intervention. The antiplatelet regimen tailoring after primary PCI (ART-PCI) trial.International journal of cardiology, 167 4
Till Althoff, M. Fischer, E. Langer, S. Ziemer, G. Baumann (2010)
Sustained enhancement of residual platelet reactivity after coronary stenting in patients with myocardial infarction compared to elective patients.Thrombosis research, 125 5
D. Sibbing, S. Braun, T. Morath, J. Mehilli, W. Vogt, A. Schömig, A. Kastrati, N. Beckerath (2009)
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.Journal of the American College of Cardiology, 53 10
V. Serebruany, S. Steinhubl, P. Berger, A. Malinin, Deepak Bhatt, E. Topol (2005)
Variability in platelet responsiveness to clopidogrel among 544 individuals.Journal of the American College of Cardiology, 45 2
K. Bliden, Joseph Dichiara, U. Tantry, A. Bassi, S. Chaganti, P. Gurbel (2007)
Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?Journal of the American College of Cardiology, 49 6
G. Parodi, R. Marcucci, R. Valenti, A. Gori, A. Migliorini, B. Giusti, P. Buonamici, G. Gensini, R. Abbate, D. Antoniucci (2011)
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.JAMA, 306 11
J. Siller-Matula, Katrin Haberl, K. Prillinger, S. Panzer, I. Lang, B. Jilma (2009)
The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation.Thrombosis research, 123 6
P. Buonamici, R. Marcucci, A. Migliorini, G. Gensini, A. Santini, R. Paniccia, G. Moschi, A. Gori, R. Abbate, D. Antoniucci (2007)
Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.Journal of the American College of Cardiology, 49 24
U. Tantry, K. Bliden, P. Gurbel (2005)
What is the best measure of thrombotic risks—pretreatment platelet aggregation, clopidogrel responsiveness, or posttreatment platelet aggregation?Catheterization and Cardiovascular Interventions, 66
S. Werns (2012)
Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention: The GRAVITAS Randomized TrialYearbook of Critical Care Medicine, 2012
G. Campo, M. Valgimigli, D. Gemmati, G. Percoco, S. Tognazzo, G. Cicchitelli, L. Catozzi, P. Malagutti, M. Anselmi, C. Vassanelli, Scapoli Gl, R. Ferrari (2006)
CLINICAL RESEARCH Interventional Cardiology Value of Platelet Reactivity in Predicting Response to Treatment and Clinical Outcome in Patients Undergoing Primary Coronary Intervention Insights Into the STRATEGY Study
The task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European association for cardio-thoracic surgery (EACTS) developed with the special contribution of the European association for percutaneous cardiovascular interventions (EAPCI) (2010)
Guidelines on myocardial revascularizationEur Heart J, 31
M. Sousa‐Uva, A. Ahlsson, U. Benedetto, R. Byrne, V. Falk, S. Windecker, Rashmi Yadav, M. Zembala (2014)
The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developedwiththespecial contribution of theEuropeanAssociationof Percutaneous Cardiovascular Interventions (EAPCI)
S. Mehta, J. Bassand, S. Chrolavicius, R. Diaz, J. Eikelboom, K. Fox, C. Granger, S. Jolly, C. Joyner, H. Rupprecht, P. Widimsky, Rizwan Afzal, J. Pogue, S. Yusuf (2010)
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.The New England journal of medicine, 363 10
Sandra Penz, I. Bernlochner, Orsolya Tóth, R. Lorenz, A. Calatzis, W. Siess (2010)
Selective and rapid monitoring of dual platelet inhibition by aspirin and P2Y12 antagonists by using multiple electrode aggregometryThrombosis Journal, 8
P. Wenaweser, J. Dörffler-Melly, Katja Imboden, S. Windecker, M. Togni, B. Meier, A. Haeberli, O. Hess (2005)
CLINICAL RESEARCH Interventional Cardiology Stent Thrombosis Is Associated With an Impaired Response to Antiplatelet Therapy
J. Snoep, M. Hovens, J. Eikenboom, J. Bom, J. Jukema, M. Huisman (2007)
Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis.American heart journal, 154 2
G. Yong, J. Rankin, L. Ferguson, J. Thom, J. French, D. Brieger, D. Chew, R. Dick, D. Eccleston, B. Hockings, D. Walters, A. Whelan, J. Eikelboom (2009)
Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in AcuAmerican heart journal, 157 1
P. Wenaweser, O. Hess (2005)
Stent thrombosis is associated with an impaired response to antiplatelet therapy.Journal of the American College of Cardiology, 46 5
D. Angiolillo, A. Fernández-Ortiz, E. Bernardo, F. Alfonso, C. Macaya, T. Bass, M. Costa (2007)
Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives.Journal of the American College of Cardiology, 49 14
R. Paniccia, E. Antonucci, N. Maggini, E. Romano, A. Gori, R. Marcucci, D. Prisco, R. Abbate (2009)
Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy.American journal of clinical pathology, 131 6
R. Marcucci, A. Gori, R. Paniccia, B. Giusti, S. Valente, C. Giglioli, P. Buonamici, D. Antoniucci, R. Abbate, G. Gensini (2009)
Cardiovascular Death and Nonfatal Myocardial Infarction in Acute Coronary Syndrome Patients Receiving Coronary Stenting Are Predicted by Residual Platelet Reactivity to ADP Detected by a Point-of-Care Assay: A 12-Month Follow-UpCirculation, 119
S. Matetzky, P. Fefer, B. Shenkman, D. Varon, N. Savion, H. Hod (2008)
Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction.The American journal of cardiology, 102 5
Price (2011)
Standard- vs. high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention. The GRAVITAS randomized trialJAMA, 305
Campo (2006)
Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention. Insights into the STRATEGY studyJ Am Coll Cardiol, 48
Stefan Chairperson, D. Norway, L. Badano, M. Borger, A. Gershlick, S. Halvorsen, J. Knuuti, M. Lenzen, K. Mahaffey, Lars Sweden, S. James (2012)
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
T. Geisler, D. Grass, B. Bigalke, K. Stellos, T. Drosch, Klaus Dietz, Christian Herdeg, M. Gawaz (2007)
The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) scoreJournal of Thrombosis and Haemostasis, 6
Deepak Bhatt, J. Scheiman, N. Abraham, E. Antman, Francis Chan, C. Furberg, David Johnson, K. Mahaffey, E. Quigley (2008)
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.Circulation, 118 18
(2007)
Pharmacokinetics and pharmacodynamics of AZD6140, the first reversible oral P2Y12 receptor antagonist, administered with aspirin
S. Matetzky, B. Shenkman, V. Guetta, M. Shechter, R. Beinart, I. Goldenberg, I. Novikov, H. Pres, N. Savion, D. Varon, H. Hod (2004)
Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial InfarctionCirculation: Journal of the American Heart Association, 109
Objectives The present trial aims at examining whether antiplatelet regimen modification, guided by assessment of the on‐treatment platelet reactivity, might result with clinical benefit in moderate to high‐risk patients with ST‐elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). Background High platelet reactivity has been associated with an increased rate of ischemic events after PCI. Recent large trials did not show a clinical benefit of platelet reactivity‐guided therapy modification in acute coronary syndrome patients treated by PCI. Methods PLATFORM is an investigator‐initiated, prospective, randomized, parallel‐group, controlled clinical trial. Approximately 632 STEMI patients with intermediate to high‐risk (RISK‐PCI score >3) clinical features undergoing PPCI will be randomly allocated to treatment modification or standard therapy. Low responders to aspirin will receive 200 mg aspirin for 30 days. Low responders to clopidogrel will receive 180 mg ticagrelor for 1 year. The primary end‐point is the time to the first composite major adverse cardiovascular events (MACE) including death, nonfatal infarction, stroke, or immediate target vessel revascularization. Key safety end‐point is the rate of TIMI major bleeding unrelated to coronary artery bypass graft surgery. Our secondary end‐points are individual components of MACE, definite stent thrombosis, total bleeding, and the need for blood transfusions. Patients will be followed‐up at 30 days and at 1 year after PPCI. Conclusion PLATFORM will determine whether the platelet reactivity‐guided use of ticagrelor in combination with 200 mg aspirin, compared with standard antiplatelet regimen, improves clinical outcome in moderate to high‐risk STEMI patients undergoing PPCI. Clinical Trial Registration U.S. National Institutes of Health (NIH) at www.clinicaltrials.gov. ClinicalTrials.gov Identifier: NCT01739556, and Current Controlled Trials at www.controlledtrials.com. International Standard Randomized Controlled Trial Number ISRCTN83081599. (J Interven Cardiol 2013;26:221–227)
Journal of Interventional Cardiology – Wiley
Published: Jun 1, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.